On July 2, 2024, Liaoning Daewoong Pharmaceutical Co., Ltd. and Shenyang DASAN Pharmaceutical Technology Co., Ltd. reached a significant cooperation agreement in the field of oral solutions, jointly signing a project cooperation agreement.
Attending the signing ceremony from Liaoning Daewoong Pharmaceutical were General Manager Moon Ji-young, Director Pan Yue, Head of Business Management Department Zhou Jihong, Director of the Research Institute Kim Soon-hee, as well as Kim Gwan-young, Head of the Yongin Research Center in Korea, and Jo Sang-eun, Head of the DP Analysis Group/CMCRA Group.From the Korean side, Ryu Jun-ho, Head of the New Business Development Department at Dasan Pharmaceutical Korea, attended. Representing Shenyang DASAN were Vice Chairman Liu Zhenhao, General Manager Yan Dong, Deputy General Manager of Production Chen Xu, and Administration Department Manager Li Yanshu.
Under the cooperation agreement, both parties will jointly develop projects related to oral solutions, covering collaboration in R&D, manufacturing, market promotion, and other aspects. Liaoning Daewoong Pharmaceutical will leverage its extensive pharmaceutical manufacturing experience and technical support, working together with Shenyang DASAN to develop and produce oral solution products. Both parties stated that this project cooperation will fully leverage their respective strengths, achieve resource sharing, and bring more innovative results to the oral solution field.
Daewoong Pharmaceutical Korea established specialized liquid formulation production facilities and a research institute in Liaoning Daewoong in 2013. From R&D to production, it operates independently, centered around core Chinese talent. Based on its main liquid formulation products, the company is also expanding its business through new ventures such as health supplements and cosmetics. Liaoning Daewoong not only meets domestic demand in China but is also striving to realize its vision of becoming an international manufacturing hub exporting to Korea, Asia, Europe, the Americas, and worldwide.
Shenyang DASAN Pharmaceutical Technology Co., Ltd. was established in July 2014. In August 2020, the company introduced strategic investment from Dasan Pharmaceutical Korea, officially becoming a Sino-Korean joint venture. Shenyang DASAN is a high-tech enterprise primarily focused on the research and development of novel drug delivery systems (DDS), dedicated to transforming DDS technologies into industrial applications. In partnership with Dasan Pharmaceutical Korea, a company specializing in advanced drug delivery technology research and production, Shenyang DASAN has invested over RMB 10 million to establish technology development platforms for taste-masking, poorly soluble drug microencapsulation, and sustained/controlled-release pellets.
Posting Date：2024-07-05
Views： 
Previous：
Back to List